Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PRTA

PRTA - Prothena Corp PLC Stock Price, Fair Value and News

$9.14-0.59 (-6.06%)
Market Closed

77/100

PRTA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

77/100

PRTA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$15

Target 3M

$11.44

Target 6M

$13.08

PRTA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PRTA Price Action

Last 7 days

-5.6%

Last 30 days

-3.6%

Last 90 days

-12.8%

Trailing 12 Months

-42.7%

PRTA RSI Chart

PRTA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PRTA Valuation

Market Cap

492.0M

Price/Earnings (Trailing)

-1.75

Price/Sales (Trailing)

4

EV/EBITDA

-0.73

Price/Free Cashflow

-2.62

PRTA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$15

Target 3M

$11.44

Target 6M

$13.08

PRTA Fundamentals

PRTA Revenue

Revenue (TTM)

135.4M

Rev. Growth (Yr)

148.97%

Rev. Growth (Qtr)

-45.36%

PRTA Earnings

Earnings (TTM)

-280.5M

Earnings Growth (Yr)

38.07%

Earnings Growth (Qtr)

70.95%

PRTA Profitability

EBT Margin

-176.30%

Return on Equity

-95.07%

Return on Assets

-79.53%

Free Cashflow Yield

-38.22%

PRTA Investor Care

Shares Dilution (1Y)

0.04%

Diluted EPS (TTM)

-5.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240221.2M218.2M135.4M
202354.9M57.6M141.0M91.4M
2022163.9M127.2M90.6M53.9M
202150.8M100.7M150.6M200.6M
2020769.0K797.0K749.0K853.0K
2019914.0K802.0K752.0K814.0K
201820.9M14.2M7.6M955.0K
20177.7M14.3M20.9M27.5M
20161.3M1.3M1.2M1.1M
201538.5M26.2M13.9M1.6M
201421.0M30.9M40.9M50.9M
20132.4M1.9M1.1M11.0M
20121.0M1.6M2.1M2.7M
2011000507.0K
20100001.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Prothena Corp PLC

PRTA
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
 CEO
 WEBSITEprothena.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES127

Prothena Corp PLC Frequently Asked Questions

PRTA is the stock ticker symbol of Prothena Corp PLC. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Prothena Corp PLC is 492.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PRTA's fair value in chart for subscribers.

The fair value guage provides a quick view whether PRTA is over valued or under valued. Whether Prothena Corp PLC is cheap or expensive depends on the assumptions which impact Prothena Corp PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRTA.

As of Wed Jan 28 2026, PRTA's PE ratio (Price to Earnings) is -1.75 and Price to Sales (PS) ratio is 4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRTA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Prothena Corp PLC has provided -0.135 (multiply by 100 for percentage) rate of return.